 |
|
|
| |
Durability of Sustained Virologic Response and Liver-Related Safety in Patients Treated With Glecaprevir/Pibrentasvir:
A Long-Term Follow-Up Study
|
| |
| |
Reported by Jules Levin
AASLD 2018 San Francisco Nov 9-13
Franco Felizarta1, Humberto Aguilar2, Armen Asatryan3, Fred Poordad4, Kosh Agarwal5, Frederik Nevens6, Tarek Hassanein7, Graham R Foster8, Reem Ghalib9, David Shaw10, David Pugatch3, Sandra Lovell3,
Teresa I Ng3, Federico J Mensa3, Edward Gane11
1Private Pract ce, Bakersfield, California, United States; 2Louisiana Research Center, Shreveport, Louisiana, United States; 3AbbVie Inc., North Chicago, Illinois, United States; 4The Texas Liver Insti tute, University of Texas Health, San Antonio, Texas, United States; 5Institute of Liver Studies, Kings College Hospital, London, United Kingdom; 6Dept of Gastroenterology and Hepatology, University Hospital KU Leuven, Leuven, Belgium; 7Southern California GI and Liver Centers and Southern California Research Center, Coronado, California, United States;
8Queen Mary University of London, Barts Health, London, United Kingdom; 9Texas Clinical Research Institute, Arlington, Texas, United States; 10Royal Adelaide Hospital, Adelaide, South Australia, Australia; 11Auckland Clinical Studies, Auckland, New Zealand
|
| |
|
|
|
|
|
